Kezdőlap・Részvénylista・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Lezárt

5.1 12.33

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

4.99

Maximum

5.11

Fő mutatók
By Trading Economics
Bevétel	-136K -35M
Egy részvényre jutó nyereség	-0.503
Munkavállalók	106
EBITDA	2.2M -35M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+30.53% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 4.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	34M 329M
Előző nyitás	-7.23
Előző zárás	5.1

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 18. 23:51 UTC

Cryptocurrency Gains Amid Investor Shift from Gold, While Geopolitical Tensions and Economic Data Loom Over Financial Markets.

2026. júl. 18. 23:51 UTC

Bitcoin and Ethereum rise amid investor shift from gold, while geopolitical tensions and U.S. Treasury shifts signal potential market volatility ahead of key economic data releases.

2026. júl. 18. 23:51 UTC

Bitcoin and Ethereum rise as investors shift from gold amid market volatility, while U.S. labor participation hits a 50-year low and geopolitical tensions escalate in the Middle East.

2026. júl. 18. 23:51 UTC

Bitcoin and Ethereum gain momentum amid investor shift from gold, while geopolitical tensions and upcoming economic data influence market sentiment.

2026. júl. 18. 23:41 UTC

Canada's Retail Sales Ex Autos MoM report on July 23, 2026, forecasts modest growth at 0.4%, amid cautious market sentiment due to geopolitical tensions and economic uncertainties.

2026. júl. 18. 23:41 UTC

Chicago Fed National Activity Index Release on July 23, 2026, Expected to Reflect Economic Fluctuations Amid Geopolitical Tensions and Rising Oil Prices.

2026. júl. 18. 23:31 UTC

ECB Set to Raise Interest Rates Amid Rising Inflation Concerns Driven by Geopolitical Tensions on July 23, 2026.

2026. júl. 18. 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Hold Steady at 2.25% Amid Geopolitical Tensions and Inflation Concerns

2026. júl. 18. 23:21 UTC

China's Loan Prime Rate (LPR) 1Y set for July 20, 2026 at a forecasted 0.03%, amid cautious investor sentiment and rising inflation concerns.

2026. júl. 18. 23:21 UTC

China's Loan Prime Rate Expected to Remain Steady at 3.50% for Five Years Amid Stable Market Sentiment

2026. júl. 18. 22:51 UTC

Japan's Inflation Rate YoY Release on July 23, 2026 Sparks Concerns Over Economic Pressures and Market Volatility Amid Rising Interest Rates.

2026. júl. 18. 22:51 UTC

Japan's Core Inflation Rate YoY Expected to Rise to 1.6% Amidst CFO Concerns Over Economic Pressures and Geopolitical Tensions

2026. júl. 18. 22:41 UTC

Mortgage Rates Hit Nine-Month High Amid Inflation Concerns and Cautious Market Sentiment Ahead of Upcoming Data Release.

2026. júl. 18. 22:41 UTC

Canada's Inflation Rate Expected to Drop Significantly Amid Geopolitical Tensions and Recent Price Declines

2026. júl. 18. 22:41 UTC

Canada's Inflation Rate Expected to Decline Slightly in June Amid Geopolitical Tensions and Volatile Market Conditions

2026. júl. 18. 22:41 UTC

Canada's Core Inflation Rate Release on July 20, 2026: Market Anticipates Lower Figures Amid Geopolitical Tensions and Recent CPI Drop.

2026. júl. 18. 22:31 UTC

Japan's June 2026 export growth forecasted at 0.186%, amid market volatility and geopolitical tensions impacting major exporters.

2026. júl. 18. 22:31 UTC

Japan's Balance of Trade report predicts a -120 billion yen deficit amid rising import costs and negative market sentiment, as stock indices decline due to global economic concerns.

2026. júl. 18. 22:31 UTC

Brazil's Central Bank to announce SELIC interest rate decision on July 20, 2026, amid stable market sentiment.

2026. júl. 18. 22:31 UTC

UK Consumer Confidence Expected to Decline to -21.0 Amid Rising Inflation and Geopolitical Tensions

2026. júl. 18. 22:21 UTC

Australia's S&P Global Services PMI Flash Release on July 23, 2026: Key Indicator Amid Mixed Market Sentiment and Inflation Concerns.

2026. júl. 18. 22:21 UTC

Optimism Grows Ahead of Australia's S&P Global Manufacturing PMI Flash Release Amid Strong Industrial Performance and Positive Investor Sentiment

2026. júl. 18. 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Pressures and Geopolitical Tensions on July 23, 2026.

2026. júl. 18. 22:01 UTC

South Korea's Q2 GDP Growth Rate Estimate Set for July 22 Amid Cautious Optimism and External Concerns.

2026. júl. 18. 22:01 UTC

South Korea's Upcoming GDP Growth Rate Release on July 22, 2026, Sparks Investor Anxiety Amid Geopolitical Tensions and Foreign Sell-Offs.

2026. júl. 18. 21:11 UTC

UK Factory Orders Forecasted at -40.0 Amid Mixed Sentiment and Economic Pressures Ahead of July 2026 Release

2026. júl. 18. 21:11 UTC

UK CBI Business Optimism Index for Q3 2026 set to reveal cautious optimism amid geopolitical tensions and inflationary pressures.

2026. júl. 18. 20:51 UTC

Correlated Moves

Macro News

Bitcoin is trading higher today amid rising geopolitical tensions and crude oil prices. Ethereum's movement reflects similar market dynamics in the cryptocurrency sector.

2026. júl. 18. 20:01 UTC

Macro News

Crude oil prices rose in after-market hours amid escalating geopolitical tensions affecting shipping routes, particularly following military actions involving Iran and U.S. forces.

2026. júl. 18. 20:01 UTC

API Crude Oil Stock Change Report Set for July 21, Amid Geopolitical Tensions Driving Price Volatility and Supply Concerns.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

30.53% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 6.67 USD 30.53%

Magas 10 USD

Alacsony 4 USD

7 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

7 ratings

Vétel

Tartás

Eladás

7 Wall Street elemző célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.